Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle? by Passiglia, Francesco & Novello, Silvia
Page 1 of 4
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(Suppl 2):S120atm.amegroups.com
Editorial
Immunotherapy in first line for extensive-stage small-cell lung 
cancer: another piece is going to fill the puzzle? 
Francesco Passiglia, Silvia Novello
Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy 
Correspondence to: Silvia Novello, MD, PhD, Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy. 
Email: silvia.novello@unito.it.
Provenance: This is an invited Editorial commissioned by Section Editor Song Xu, MD, PhD (Department of Lung Cancer Surgery, Tianjin Medical 
University General Hospital, Tianjin, China; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer 
Institute, Tianjin, China).
Comment on: Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N 
Engl J Med 2018;379:2220-9. 
Submitted Nov 30, 2018. Accepted for publication Dec 10, 2018.
doi: 10.21037/atm.2018.12.25
View this article at: http://dx.doi.org/10.21037/atm.2018.12.25
In The New England Journal of Medicine, Horn and 
colleagues have recently published the results of the 
IMPower133, a randomized, placebo-controlled, phase 
III trial, combining the programmed-death ligand 1 
(PD-L1) inhibitor atezolizumab or placebo with carboplatin 
and etoposide in treatment-naive patients with extensive-
stage small-cell lung cancer (SCLC) (1). The study met its 
co-primary end-points, showing a significant increase of 
progression free survival (PFS) in favour of atezolizumab 
as compared to placebo arm [5.2 vs. 4.3 months; hazard 
ratio (HR): 0.77; 95% CI, 0.62 to 0.96; P=0.02]. The 
addition of atezolizumab to chemotherapy resulted also in 
a significantly longer overall survival (OS) in the intention-
to-treat population (12.3 vs. 10.3 months; HR: 0.70; 95% 
CI, 0.54 to 0.91; P=0.007), while no differences in response 
rate (60.2% vs. 64.4%) as well as in the duration of response 
(4.2 vs. 3.9 months) were observed between the two 
treatment arms. The survival benefit was confirmed across 
all pre-defined subgroups selected by clinical, pathological 
and molecular characteristics. As attended, the percentage 
of patients who reported immune-related adverse-events 
(AEs) was significantly higher (39.9% vs. 24.5%) in the 
atezolizumab arm, with grade 1–2 rash and hypothyroidism 
being the most common. Finally, the percentage of AEs 
leading to withdrawal from any treatment nearly tripled 
with atezolizumab as compared to placebo arm. 
Since SCLC is almost always smoking-induced and 
genetically instable, it has been historically considered 
a potential good candidate for immunotherapy (2). 
The notion that paraneoplastic syndromes are often 
accompanied by T-cell mediated antitumor immunity (3), 
together with the recent evidence that SCLC has one of the 
highest rate of mutation burden (4), have further enhanced 
the hope for an efficacious application of checkpoint 
inhibitors in SCLC treatment. Both PD-1 inhibitors 
nivolumab (5,6) and pembrolizumab (7) as well as the anti-
PD-L1 atezolizumab (8) have shown very promising activity 
and tolerable safety profile in phase I studies including 
heavily pre-treated patients with extensive-stage SCLC. 
Recently, the KEYNOTE-158 study (9) confirmed single 
agent pembrolizumab as an effective treatment option 
in about 100 patients with relapsed SCLC, showing an 
objective response rate (ORR) of 18.7%, median PFS of 
2.0 months, and median OS of 9.1 months. Conversely the 
phase 3 randomized CheckMate-331 study did not meet 
primary end-point of OS with nivolumab versus single 
agent chemotherapy in previously treated SCLC patients. 
The majority of phase II–III trials moving checkpoint 
inhibitors in front-line setting failed to demonstrate 
any relevant impact on patients’ survival. Particularly, a 
phase II single arm study demonstrated that maintenance 
therapy with pembrolizumab after frontline platinum-
etoposide did not improve survival outcomes of 45 patients 
with extensive stage SCLC (10) as compared to historical 
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control. Similarly the CheckMate 451 study did not show 
any survival benefit with nivolumab plus ipilimumab 
versus placebo as maintenance therapy in patients with 
extensive-stage SCLC who completed first-line platinum-
chemotherapy. Finally, the addition of the CTLA-4 
inhibitor ipilimumab to first-line platinum etoposide 
showed no improved efficacy as compared to chemotherapy 
alone (11). The results of the IMPower133 trial interrupted 
the negative trend of upfront immunotherapy in SCLC. As 
recently observed in non-small cell lung cancer (NSCLC) 
(12,13), such trial demonstrated that combining checkpoint 
inhibitors with platinum chemotherapy is an effective and 
tolerable strategy also in this “recalcitrant” disease. Since 
the advent of platinum-chemotherapy in 1990s, this is the 
first study showing a modest, but significant improvement 
in frontline SCLC standard of care. Although the median 
OS improvement produced by the addition of atezolizumab 
is just equal to 2 months, the HR of 0.70 along with an OS 
increase higher than 10% at 1 year in the atezolizumab 
group, resulted in a preliminary score of 2 according to the 
last version of the European Society of Medical Oncology 
(ESMO) Magnitude of Clinical Benefit Scale (14), which 
could be further upgraded if a significant OS increase at 
2 years will be confirmed. For this reason, final OS data as 
well as long term follow-up will be crucial to determine the 
proportion of patients who will experience long-term benefit 
from combination therapy, and to definitively establish the 
clinical impact derived from the addition of atezolizumab to 
first-line platinum chemotherapy. The main critics regard 
the design of the trial. Although the control arm, including 
4 cycles of carboplatin plus etoposide, performed as 
predicted, however a maximum of 6 cycles of platinum-
chemotherapy is currently recommended by all international 
guidelines (15,16) and this is the common approach in 
real-world practice. Furthermore, the specific impact of 
immune-checkpoint inhibitor maintenance therapy on the 
final OS observed in the IMPower133 remained unclear. 
Finally, only 7.4% of patients in the control arm received 
atezolizumab in second-line, thus we currently do not 
know whether upfront combination is more effective than 
sequential treatment in the overall SCLC population. This 
study clearly showed, once again, as about 50% of patients 
with extensive-stage SCLC will never receive second-line 
therapy after platinum-combinations because of a rapid 
worsening of clinical conditions, suggesting that the upfront 
use of atezolizumab could benefit a larger population than if 
it is used in later lines of treatment. 
Concerning the effectiveness of immuno-chemotherapy 
combination in SCLC patients with brain metastasis, 
although the subgroup analysis of the IMPower133 showed 
that they do not derive any benefit from the addition of 
atezolizumab, the low number of patients included do 
not allow to draw any definitive conclusions, ensuring 
further investigation in dedicated trials. The biological 
mechanisms underlying the effectiveness of atezolizumab-
chemotherapy regimen as well  as the ipil imumab 
CTLA-4 inhibition failure in a similar SCLC naive 
population remain a hot topic for translational research. 
Both CTLA-4 and PD-1 are inhibitory checkpoints 
playing a key role in the modulation of anti-tumor immune 
response. In detail, CTLA-4 is implicated in the activation 
stage of T-cell priming, occurring in regional secondary 
lymphoid organs, whereas PD-1 acts in the secondary step 
of T-cell activation process, binding its natural ligands, 
PD-L1 and PD-L2, which are expressed on tumor, stroma, 
and immune cells located in the tumor microenvironment 
(17,18). The understanding of such biological mechanisms 
may provide a partial explanation to the survival differences 
observed in the randomized clinical trials, ensuring further 
investigation in translational studies. 
Developing biomarker-driven treatment strategies is an 
actual challenge of clinical research, involving also trials 
with immunotherapy. The significant correlation between 
tumor mutational burden (TMB) and immunotherapy 
activity observed in pre-treated patients with SCLC (19), 
was not confirmed in the IMPower133 trial, since the 
analysis of blood-based TMB levels was not predictive of 
atezolizumab benefit both in terms of PFS and OS (1), 
ultimately questioning the utility of TMB in the selection 
of SCLC patient candidates to upfront combination. The 
predictive role of tumor PD-L1 expression has not been 
evaluated in the IMPower133 trial, since data emerging 
from phase I studies (5,7) clearly demonstrated that 
PD-L1 has generally low expression on tumor cells and did 
not correlate to immunotherapy efficacy. Conversely, the 
expression of PD-L1 in the stroma seems to be higher and 
significantly associated with survival outcomes of pre-treated 
patients included in the KEYNOTE-028 and 158 trials 
(7,8), and its predictive value is currently investigated in the 
first-line KEYNOTE-604 study comparing Pembrolizumab 
plus platinum-chemotherapy vs. chemotherapy alone in 
extensive-stage, naive SCLC patients. Even if crucial, the 
biomarker-driven treatment strategy will inevitably meet 
several criticisms, considering the limited, low quality, and 
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often cytological samples that are almost always used to 
obtain SCLC diagnosis, likely imposing a radical change of 
tissue collection practice. In conclusion, the study of Horn 
et al. represents a significant attempt to the improvement of 
upfront SCLC therapy. Adding atezolizumab to platinum-
chemotherapy produced a statistically significant and 
durable increase of OS together with a modest increment 
of immune-related toxicities, emerging as new potential 
standard of care in the treatment of this high aggressive and 
poor prognosis disease. However, to clearly establish also a 
“clinical significant impact”, final OS data as well as long-
term follow-up will be crucial. Additional data supporting 
the use of upfront immune-chemotherapy combinations 
are eagerly awaited and the ongoing randomized phase 
III KEYNOTE-604 and CASPIAN studies, respectively 
evaluating the addition of pembrolizumab or durvalumab/
tremelimumab to upfront platinum-combinations will 
provide important results within next year. Considering 
the advent of new promising drugs/combinations, the main 
challenge will be how to integrate all these agents and 
ultimately fill the puzzle of SCLC treatment. 
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